No Patient Left Behind – Connecting Rare Disease Patients to Orphan Drug Manufacturers

July 28, 2016

If you have ever worked with Orphan Drugs, you know finding appropriate patients is a major commercial challenge. Pharmaceutical sponsors of Orphan Drugs often lack the infrastructure and capabilities necessary to identify physicians who diagnose, treat, and manage these rare patients. TrialCard developed a proven model for making this critical match and has helped many patients gain access to the therapy they so desperately need.

Spotlight

Fort Dodge Animal Health

Fort Dodge Animal Health began in 1912 as a small serum manufacturer based in Fort Dodge, Iowa. Today, the company is headquartered in Overland Park, Kan., and has emerged as a leading global manufacturer of animal health products for the livestock, companion animal, equine, swine, and poultry industries. Fort Dodge is a committed partner to veterinary practitioners, livestock producers, and pet owners worldwide, and is dedicated to meeting their needs and making a difference in the future of animal health.

OTHER WHITEPAPERS
news image

A Vision for the Global Generic and Biosimilar Medicines Industry

whitePaper | May 22, 2021

One of the key roles of the generic and biosimilar medicines industry is specifically to promote the widest possible access to affordable medicines with high quality, safety, and efficacy for patients globally by introducing competition into the markets. Despite the many hurdles, the generic medicines companies have clearly lived up to the challenges posed by the pandemic as it is an industry that is quick to adapt and agile in manufacturing scale-up. During the outbreak of COVID-19, this industry was providing most of the medicines needed in Intensive Care Units to ventilate critically ill COVID patients. It is also providing most of the quality medicines dispensed around the world, especially for increasingly prevalent chronic diseases and is therefore a strong contributor to health outcomes globally.

Read More
news image

Pharma R And D Review

whitePaper | February 11, 2021

Welcome to Pharmaprojects’ 2021 review of trends in pharmaceutical R&D. For almost 30 years now, I’ve been taking an annual look at the evolution of pharma R&D, and in this article I’ll examine the state of play at the start of 2021.

Read More
news image

The Impact of Rising Generic Drug Prices on the U.S. Drug Supply Chain

whitePaper | April 16, 2020

Over the past two years, the pharmacy industry has seen unprecedented increases in the prices of generic drugs, causing unexpected cost increases for payers and consumers, and spurring an investigation by the United States Congress. High generic drug prices have had an adverse effect on almost everyone in the pharmaceutical supply chain. Consumers face higher co-pays and prices and health plans are dealing with higher drug spend. Physicians are finding the need to prescribe alternative drug therapies while dealing with angry patients.

Read More
news image

Pharmaceutical Sales Strategies Post-COVID-19: The Benefits of Virtual Engagement

whitePaper | April 7, 2021

In less than a week, in the face of a pandemic, the pharmaceutical sales model changed forever. In-person healthcare provider (HCP) visits came to a screeching halt and brand marketers scrambled to find ways to educate and engage these providers remotely. While the pandemic may have taken us by surprise, we should acknowledge that, even before the pandemic, pharmaceutical sales teams faced significant challenges. One solution for these challenges is to engage HCPs – virtually.

Read More
news image

Pharma R&D Annual Review

whitePaper | March 15, 2022

Successes in 2021 – New active substance drug launches

Read More
news image

Winning with biosimilars Opportunities in global markets

whitePaper | March 14, 2022

Over the past several years, biologics have gained significant traction in the pharmaceutical industry, representing more than $150 billion in global sales in 2013. By 2020 they are predicted to generate $290 billion in revenue and comprise 27 percent of the pharmaceutical market.i

Read More

Spotlight

Fort Dodge Animal Health

Fort Dodge Animal Health began in 1912 as a small serum manufacturer based in Fort Dodge, Iowa. Today, the company is headquartered in Overland Park, Kan., and has emerged as a leading global manufacturer of animal health products for the livestock, companion animal, equine, swine, and poultry industries. Fort Dodge is a committed partner to veterinary practitioners, livestock producers, and pet owners worldwide, and is dedicated to meeting their needs and making a difference in the future of animal health.

Events